ArrowMark Colorado Holdings’s Novartis NVS Stock Holding History

ArrowMark Colorado Holdings’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-7,433	Closed	-$573K	–	269
2015 Q4	$573K	Hold	7,433	–	–	0.02%	245
2015 Q3	$612K	Hold	7,433	–	–	0.02%	245
2015 Q2	$655K	Buy	+7,433	New	+$682K	0.02%	255

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

ArrowMark Colorado Holdings's NVS Position: Q1 2016 in Review

ArrowMark Colorado Holdings sold out of Novartis (NVS) in Q1 2016, closing a stake of 7,433 shares — an estimated $573K sold.

ArrowMark Colorado Holdings first reported a position in NVS in Q2 2015 and held it in 3 quarters. The position peaked at $655K in Q2 2015. 875 funds tracked by Wall St. Rank hold NVS as of Q1 2016.

ArrowMark Colorado Holdings reported no remaining Novartis position as of Q1 2016 after selling out during the quarter.
ArrowMark Colorado Holdings sold 7,433 Novartis shares in Q1 2016, an estimated $573K.
ArrowMark Colorado Holdings first reported a position in Novartis in Q2 2015 and held it in 3 quarters.
ArrowMark Colorado Holdings's Novartis position peaked at $655K in Q2 2015.
875 funds tracked by Wall St. Rank held Novartis as of Q1 2016.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2016, filed 16 May 2016.